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ABSTRACT
Background: Adjustment disorder with anxiety
(ADWA) is a highly prevalent condition,
particularly in primary care practice. There are
relatively few systematic treatment trials in the
area of ADWA, and there are few data on
predictors of treatment response. Etifoxine is a
promising agent insofar as it is not associated
with dependence, but in primary care settings
benzodiazepines continue to be frequently
prescribed for psychiatric symptoms. A
randomized controlled trial of etifoxine versus
alprazolam for ADWA was undertaken, focusing
on efficacy and safety measures, and including
an investigation of predictors of clinical
response.
Methods: This was a comparative, multicenter,
double-blind, randomized trial in two parallel
groups of outpatients with ADWA. One group
was treated with 150 mg/day for etifoxine, and
the other with 1.5 mg/day for alprazolam for
28 days. Patients were followed for 4 weeks of
treatment, and for an additional week after
treatment discontinuation. The primary
outcome measure was the Hamilton Anxiety
Rating Scale (HAM-A), while secondary
outcome measures included the Sheehan
Disability Scale (SDS), the Clinical Global
Impressions-Change Scale (CGI-C), and the
Self-Report for the Assessment of Adjustment
Disorders. Non-inferiority analysis was used to
assess the primary outcome measure, and a
multivariate logistic regression was employed to
investigate predictors of response.
Results: Two hundred and two adult
outpatients with ADWA were enrolled at 17
primary care sites. One hundred and seventy
seven patients completed the study (n = 87 in
the etifoxine group; n = 90 in the alprazolam
group). Etifoxine and alprazolam were
accompanied by decreases in the HAM-A at
day 28, with a difference between treatment
groups in HAM-A score of 1.78 [90% CI; 0.23,
3.33] in favor of alprazolam. However, after
medication discontinuation, HAM-A scores
continued to improve in the etifoxine group,
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but increased in the alprazolam group; the
difference between groups in mean change
between day 28 and day 35 was significant
(p = 0.019). Secondary outcome measures
showed similar results for etifoxine and
alprazolam at day 35. More treatment-related
adverse events were reported in patients treated
with alprazolam, particularly central nervous
system-related AEs, and especially after
medication discontinuation. No significant
predictors of treatment response were found.
Conclusion: This randomized controlled trial
provides support for the efficacy and safety of
etifoxine in the management of adjustment
disorder with anxiety, particularly when
treatment discontinuation data are also
assessed. Etifoxine has the important clinical
advantage of having anxiolytic effects, which
are not being associated with dependence.
Pharmacotherapy was equally efficacious in
patients with more severe anxiety symptoms
at baseline. Additional work using longer-term
follow-up and collecting data on cost-efficiency
of management options would further advance
the field of ADWA.
Funding: Sponsorship and article processing
charges for this study were provided by
Biocodex, Gentilly, France.
Keywords: Adjustment disorder with anxiety;
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INTRODUCTION
Adjustment disorders are characterized by the
development of clinically significant emotional
or behavioral symptoms in response to an
identifiable stressor or stressors [1]. In the fifth
edition of the Diagnostic and Statistical Manual
of Mental Disorders (DSM-5), adjustment
disorders are categorized as trauma- and
stressor-related disorders, alongside conditions
such as posttraumatic stress disorder [2].
Adjustment disorders are prevalent in the
community, with point prevalence estimates
ranging from 0.9% to 2.3% [3], and even higher
in clinical samples, where point prevalence
estimates range from 5% to 24%, with
adjustment disorder with anxiety (ADWA)
being the most frequent [4]. Adjustment
disorders are associated with substantial
morbidity and impaired quality of life [3, 5, 6].
Both psychotherapy and pharmacotherapy
of adjustment disorders have been investigated.
A Cochrane review of interventions to facilitate
return to work in adults with adjustment
disorders included nine studies of
psychological interventions, and concluded
that cognitive behavioral therapy (CBT) did
not significantly reduce time until return to
work, compared with no treatment [7]. There is
also a small literature on the investigation of
antidepressants and benzodiazepines for
adjustment disorder; to date, however, no
agent has been registered for this indication
[3]. In clinical practice, benzodiazepines are
very often prescribed [8], even though concerns
have been raised about the adverse event profile
of these agents, including cognitive dysfunction
and the potential risk for dependence [9].
Etifoxine is a benzoxazin drug that does not
belong to the benzodiazepine family, but that
nevertheless has anxiolytic properties [10].
Etifoxine directly interacts with the chloride
channel of the GABAA receptor complex and
therefore potentiates GABAergic synaptic
transmission [11–13]. Further, etifoxine may
have indirect effects, acting at peripheral
benzodiazepine receptors (PBR) to increase
brain neurosteroids (pregnenolone,
allopregnanolone) with anti-anxiety effects
[14, 15]. Previous trials have found that
etifoxine has similar efficacy compared to
buspirone [16] and to lorazepam [17] in
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ADWA. Furthermore, etifoxine has few adverse
cognitive or psychomotor effects and is not
associated with dependence [18].
The objective of the present study was to
compare the efficacy and safety of etifoxine
with the high potency benzodiazepine,
alprazolam, in the treatment of ADWA, and to
evaluate the persistence of clinical effects as
well as any rebound effects after treatment
discontinuation. The tertiary outcome was to




This prospective study was conducted in South
Africa as a comparative, multicenter, double-
blind, randomized trial in two parallel groups of
outpatients with ADWA. Seventeen centres in
two locations (Cape Town, Johannesburg)
participated. A non-inferiority design
comparing etifoxine with a commonly
prescribed anxiolytic agent rather than with a
placebo was chosen, and attention was paid to
the visit after treatment discontinuation.
Exploratory analyses of socio-demographic and
clinical predictors of scores on the Hamilton
Anxiety Rating Scale (HAM-A), the primary
outcome measure, were also undertaken to
determine the predictors of pharmacotherapy
response in ADWA.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in 2000
and 2008. Informed consent was obtained from
all patients for being included in the study.
Before starting the trial, all investigators
(n = 35) were trained by the study coordinator
to diagnose ADWA. The full day of training
included viewing videos of clinical cases,
training in ADWA diagnosis, and training in
study symptom scales. After the inclusion visit,
participants attended three visits: after 1 week
of treatment (day 7), at the end of the treatment
period (day 28) and 1 week after treatment
discontinuation (day 35). Efficacy and safety
measures were undertaken at each of these
visits.
ADWA patients included in the study were
randomly assigned to receive etifoxine or
alprazolam per os. A randomization list was
established and study treatments were
assigned by each investigator in ascending
order of numbering based on the
chronological enrollment order. Study drug
was to be taken daily for 28 days (one capsule
in the morning, at noon and in the evening),
at usual dosages (150 mg/day for etifoxine,
and 1.5 mg/day for alprazolam), in conformity
with the summary of product characteristics
(SmPC) of the two drugs. Study treatments
were presented as capsules identical in their
appearance.
Patients
To be eligible for inclusion, male or female
outpatients aged 18–65 years had to meet the
criteria for ADWA as defined by the DSM-IV
[19]. In addition, baseline score on the
Hamilton Anxiety Rating Scale (HAM-A) [20]
was C20, with a baseline score in at least one
of three subscales (work, family and social life)
of the Sheehan Disability Scale (SDS) [21] C5,
and a baseline score on the Montgomery–
A˚sberg Depression Rating Scale (MADRS)
[22] \20.
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Participants had no comorbid psychiatric or
substance use disorder (as assessed by the Mini-
International Neuropsychiatric Interview [23]),
no suicidal thoughts, present or past history of
epilepsy, no medical disorder physiologically
responsible for anxiety, and were not pregnant
nor breast feeding. Current or past (previous
month) treatment with benzodiazepines or
other psychotropic agents (including
alternative medicines) was not allowed.
Current treatment with drugs likely to
interfere with the metabolism of the study
treatments was also an exclusion criterion.
Efficacy and Safety Assessments
To assess the primary outcome measure, the
HAM-A Scale was employed on day 7, day 28,
and day 35. To assess the secondary outcome,
the Clinical Global Impression Scale (CGI) [24],
the SDS, and the Self-Report for the Assessment
of Adjustment Disorders [25] were also
administered at these study visits. The MADRS
was also administered at baseline.
The Self-Report for the Assessment of
Adjustment Disorders is composed of 29 items,
measuring the reactions triggered by the
stressful event. Each item was rated from 1
(never) to 4 (often), resulting in six sub-scores,
namely intrusions, avoidance, failure to adapt,
depressive mood, anxiety and impulse
disturbance [26]. This was the first use of the
scale in a clinical trial; the results collected and
the validity of the scale will be more fully
described in a separate article.
All adverse events were recorded at each
study visit and relationship to treatment was
rated according to the investigator’s judgment.
On day 35, withdrawal symptoms were assessed
with the Discontinuation-Emergent Signs and
Symptoms (DESS) Scale [27].
Statistical Analyses
Sample size was determined to achieve 80%
power to detect a difference inferior to 2.5
points in HAM-A total score on day 28 between
the two groups. The non-inferiority of etifoxine
compared to alprazolam would be demonstrated
if the upper limit of the 90% confidence interval
(CI) of the difference ‘etifoxine minus
alprazolam’ was lower than 2.5 (primary
efficacy analysis). The 2.5 cutoff was chosen in
accordance with data from two previous studies
of etifoxine in ADWA [16, 17] as well as previous
clinical trials using the HAM-A [28, 29].
All patients who received at least one dose of
study drug comprised the safety set. All
randomized patients who received at least one
dose of study drug with at least one endpoint
assessed comprised the full analysis set (FAS).
HAM-A total score was analyzed using an
analysis of covariance (ANCOVA) adjusted for
baseline score. Responder status (as assessed by
C50% decrease in HAM-A) was compared
between groups using a Chi-square test. Other
secondary outcome measures, including HAM-A
psychic and somatic sub-scores, were compared
between treatment groups using an ANCOVA or
a Wilcoxon rank-sum test, with significance
level set at 0.05. These analyses were conducted
with SAS software, version 9.1 (SAS Institute,
North Carolina).
Socio-demographic and clinical variables,
including stressor type, potentially predicting
clinical response on day 28 and day 35 were
entered into univariate logistic regressions with
the response on HAM-A Scale as the dependent
variable. Factors showing a p value less than or
equal to 0.10, and that were not significantly
associated with one another, were then entered
into a multivariate model using forward
selection, again using SAS.
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RESULTS
Demographic and Clinical Data
Between October 2011 and January 2013, 202
participants who had consulted their primary
practitioner for symptoms of ADWA were
included in the study. One patient, who
signed the informed consent but did not fully
perform the day 1 visit, was not randomized
and was excluded from all analysis populations.
Overall, 201 patients received at least one dose
of the study treatments (safety set): 100 received
etifoxine and 101 received alprazolam.
The baseline characteristics of the 201
patients from the safety set are presented in
Table 1. At inclusion, the two groups were
similar regarding nearly all the variables
assessed, with a mean age of 39.4 years (range
18–64). The percentage of female patients was
slightly higher in the etifoxine group: 76.0% vs.
70.3% in the alprazolam group. The mean
weight of etifoxine patients was somewhat
higher than alprazolam patients (80.7 and
76.4 kg, respectively), resulting in a higher
body mass index in the etifoxine group (29.1
vs. 26.8 kg m-2).
The main stressor responsible for the present
episode of ADWA was related to family/love life
(38.8% of patients), work/school (37.8%),
finance (12.4%), or other issues (10.9%). The
mean HAM-A total score at baseline was 29.9
(range 20–55), the mean (±standard deviation
[SD]) CGI severity score was 3.8 (±1.0), with
Table 1 Patients baseline characteristics (safety set)
Etifoxine (n5 100) Alprazolam (n5 101) Total (n5 201)
Female (%) 76.0 70.3 73.1
Age; mean (SD) [min–max] 40.0 (11.8) [18–62] 38.9 (12.8) [18–64] 39.4 (12.3) [18–64]
Weight; mean (SD) [min–max] 80.7 (19.4) [50–133] 76.4 (18.4) [46–133] 78.5 (19.0) [46–133]
Main stressor (%)
Family/love life 39.0 38.6 38.8
Work/school 34.0 41.6 37.8
Finance 12.0 12.9 12.4
Other 15.0 6.9 10.9
HAM-A total score; mean (SD) [min–max] 29.3 (5.9) [20–46] 30.5 (7.2) [20–55] 29.9 (6.6) [20–55]
MADRS score; mean (SD) 12.4 (4.3) 12.4 (4.9) 12.4 (4.6)
CGI severity score; mean (SD) 3.9 (1.0) (n = 98) 3.8 (1.1) (n = 98) 3.8 (1.0) (n = 196)
SDS scores; mean (SD)
Work/schoola 5.5 (2.2) (n = 84) 6.3 (2.0) (n = 84) 5.9 (2.1) (n = 168)
Social life 5.9 (2.5) 6.3 (2.0) 6.1 (2.3)
Family life 5.8 (2.3) 6.2 (2.3) 6.0 (2.3)
CGI Clinical Global Impression Scale, HAM-A Hamilton Anxiety Rating Scale, MADRS Montgomery–Åsberg Depression
Rating Scale, SD standard deviation, SDS Sheehan Disability Scale
a Subgroup of patients who worked/studied during the week preceding the study entry
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mean scores of 6 on the SDS subscales, reflecting
the presence of illness that moderately
disrupted the patients’ work, social life and
family life. Mean (±SD) score on the MADRS
was 12.4 (±4.6), indicative of low depressive
symptoms.
Patient Disposition
Thirteen patients from the etifoxine group
(13.0%) and 11 from the alprazolam group
(10.9%) prematurely discontinued the study,
mainly for adverse events (etifoxine: 4,
alprazolam: 6) and consent withdrawal
(etifoxine: 3, alprazolam: 2). Overall, 177
patients completed the study, 87 in the
etifoxine group (87.0%) and 90 in the
alprazolam group (89.1%). The mean (±SD)
treatment duration was 26.6 ± 6.9 days in the
etifoxine group (n = 99) and 27.3 ± 6.0 days in
the alprazolam group (n = 99). Based on pill
count, mean compliance rates with treatment
were 97.2% in the etifoxine group (n = 98) and
98.5% in the alprazolam group (n = 98).
Efficacy Analysis
The FAS comprised 190 patients: 95 in etifoxine
group and 95 in alprazolam group.
Improvement of anxiety symptoms on day 28
was demonstrated in both groups, as reflected
by a mean decrease in the HAM-A total score of
72.5% ± 23.8% and 79.7% ± 17.0% in the
etifoxine and alprazolam groups, respectively
(Fig. 1). The adjusted mean difference in HAM-A
score of 1.78 [90% CI; 0.23, 3.33] was in favor of
alprazolam, and as the upper limit of the 90%
CI was greater than the 2.5 reference value, the
non-inferiority of etifoxine compared with
alprazolam was not shown (Table 2). On
secondary outcome measures, there were no
significant differences between the two groups
at day 28 in the Self-Rated Assessment of
ADWA symptoms, CGI scores, responder status,
HAM-A psychic score, or SDS (Table 2) (Fig. 3).
The benefits of treatment appeared from the
first week with a mean decrease in the HAM-A
score of 51.2% ± 22.5% and 58.7% ± 18.9% in
the etifoxine and alprazolam groups,
respectively, on day 7. There was an adjusted
mean difference in HAM-A score of 2.19 [90%
CI; 0.69, 3.70] and [95% CI; 0.40, 3.99]
statistically significant in favor of alprazolam.
However, 1 week after treatment
discontinuation, HAM-A in the etifoxine
group continued to decrease (-0.6 ± 4.5),
while HAM-A in the alprazolam group
increased (?2.2 ± 7.0) (p = 0.019) (Fig. 2).
Thus, there was an adjusted mean difference
in HAM-A score of -0.93 [90% CI; -2.96, 1.10]
in favor of etifoxine, demonstrating non-
inferiority of etifoxine compared with
alprazolam at day 35 (Table 2). Similarly, on
secondary outcome measures, there were no
significant differences between groups at day 35
after treatment discontinuation, although
scores numerically favored etifoxine at the
later time point (Table 2) (Fig. 3). For example,
Fig. 1 Progression of the mean (SD) HAM-A total score
during the study (FAS). FAS Full analysis set, HAM-A
Hamilton Anxiety Rating Scale, SD standard deviation
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CGI severity score decreased between day 28
and day 35 in the etifoxine group (-0.2 ± 0.8),
while it increased in the alprazolam group
(?0.2 ± 1.0), resulting in a significant
difference between groups in the score change
from day 28 to day 35 (p = 0.004).
Adverse Events
Adverse events were analyzed on the safety set
(n = 201 patients). During the study, 35 patients
(35.0%) in the etifoxine group experienced at
least one adverse event compared to 48 (47.5%)
in the alprazolam group (Table 3). During the
treatment period (day 1–day 28), 35 patients
(35.0%) experienced 70 adverse events in the
etifoxine group compared to 44 patients
(43.6%) who had 61 adverse events in the
alprazolam group (p = 0.214). Adverse events
were, however, markedly more often rated as
‘‘treatment-related’’ by the investigators in the
alprazolam group (62.3%; 13 ‘‘possibly’’ and 25
‘‘probably’’ related) than in the etifoxine group
(34.3%; 13 ‘‘possibly’’ and 11 ‘‘probably’’ related)
(p = 0.002).
Adverse events resulted in treatment
withdrawal in 7 patients from the etifoxine
group and 6 patients from the alprazolam
group, mainly due to central nervous system
(CNS) and gastrointestinal symptoms. Indeed,
CNS symptoms were the most frequent adverse
events and were reported by 16.0% and 24.8%
of the patients in the etifoxine and alprazolam
group, respectively. Notably, many more
patients reported episodes of ‘‘somnolence’’ or
‘‘sedation’’ in the alprazolam group (14 patients)
than in the etifoxine group (4 patients).
Additionally, ‘‘fatigue’’ events were only
observed in patients who received alprazolam
(4 patients). Gastrointestinal symptoms were
also quite frequent and were reported by 12
patients in the etifoxine group and 8 in the
alprazolam group. These various differences did
not, however, reach statistical significance.
Table 2 Mean HAM-A scores adjusted for day 1 value (±SE) and percentage of responders during the study (FAS)
Etifoxine (n5 95) Alprazolam (n5 95)
Raw mean HAM-A score on day 1 (±SD) 29.3 (6.0) 30.4 (7.4)
Adjusted mean HAM-A score on day 7 (±SE) 14.49 (0.64) 12.29 (0.64)
Adjusted mean difference (±SE) - [90% CI] 2.19 (0.91) - [0.69 to 3.70]
Adjusted mean HAM-A score on day 28 (±SE) 7.95 (0.66) (n = 90) 6.17 (0.66) (n = 91)
Adjusted mean difference (±SE) - [90% CI] 1.78 (0.94) - [0.23 to 3.33]
Adjusted mean HAM-A score on day 35 (±SE) 7.24 (0.87) (n = 87) 8.17 (0.86) (n = 90)
Adjusted mean difference (±SE) - [90% CI] -0.93 (1.23) - [-2.96 to 1.10]
Respondersa/remittersb (%)
Day 7 52.6/17.9 (n = 95) 65.3/21.1 (n = 95)
Day 28 85.6/55.6 (n = 90) 92.3/67.0 (n = 91)
Day 35 80.5/64.4 (n = 87) 75.6/58.9 (n = 90)
CI conﬁdence interval, FAS full analysis set, HAM-A Hamilton Anxiety Rating Scale, SD standard deviation, SE standard
error
a Patients with a decrease from baseline in the HAM-A total score C50%
b Patients with a HAM-A total score B7
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Four serious adverse events were reported by
four patients (two in each group). In the
etifoxine group, one patient underwent an
arthroscopy consequent to a knee ligament
injury and a second patient had a laparoscopic
cholecystectomy to treat an episode of gallstone
cholecystitis. Relationship with study treatment
was judged by investigators ‘‘unrelated’’ and
‘‘unknown’’, respectively. In the alprazolam
group, one patient had suicidal ideation and
was diagnosed with temporal lobe epilepsy,
while a second one took an overdose of study
treatment. Investigators considered the
Fig. 2 a Mean (SD) HAM-A total score and b CGI
severity score at day 28 and day 35 (FAS). CGI Clinical
Global Impression, FAS full analysis set; HAM-A
Hamilton Anxiety Rating Scale, SD standard deviation
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relationship with study treatment ‘‘unlikely’’
and ‘‘possible’’, respectively for these events.
On day 35, the mean total DESS score was
similar in the etifoxine and the alprazolam
groups, with values of 2.0 (±4.4) and 3.0 (±5.4),
respectively. After treatment discontinuation,
notably more patients (11%) experienced
adverse events in the alprazolam group (16
events) than in the etifoxine group (4% and 4
events) (p = 0.063). Among these adverse
events, 50% were treatment-related in the
alprazolam group (5 ‘‘possible’’ and 3
‘‘probable’’) compared to none in the etifoxine
group.
Predictor Analyses
Univariate analyses indicated that women
responded better to treatment (p = 0.045 at
day 28, p = 0.017 at day 35), and that patients
with high MADRS baseline scores responded
worse to treatment (p = 0.025) at day 35.
However, there was no significant link
between response to treatment and the
treatment administered (alprazolam or
etifoxine), HAM-A baseline score, or other
socio-demographic and clinical variables at
these time points. Furthermore, on
multivariate analysis, there were no significant
predictors of treatment response.
DISCUSSION
The main findings of this study were that (1)
HAM-A scores favored alprazolam compared to
etifoxine at day 7 and at day 28, with significant
differences at day 7 and non-inferiority of
etifoxine unable to be demonstrated at day 28,
(2) HAM-A scores slightly favored etifoxine
compared to alprazolam after treatment
discontinuation, with a significant difference
in HAM-A score change apparent during this
last week of the study, (3) there were more
adverse events in the alprazolam group,
particularly central nervous system-related
Table 3 Safety results (safety set)









Adverse events 74 35 (35.0) 77 48 (47.5)
Serious adverse events 2 2 (2.0) 2 2 (2.0)
Treatment-emergent adverse eventsa 70 35 (35.0) 61 44 (43.6) 0.214
Post-treatment adverse eventsb 4 4 (4.0) 16 11 (10.9) 0.063
Increase in HAM-A total score C5
between day 28 and day 35
11 (12.6) n = 87 21 (23.3) n = 90 0.065
HAM-A Hamilton Anxiety Rating Scale
* Comparison of % of patients
a Events that started during treatment period, between day 1 and day 28
b Events that started after treatment stop, between day 28 and day 35
Fig. 3 a Progression of the mean HAM-A total score
during the study, b progression of the HAM-A psychic
sub-score and c progress of the HAM-A somatic sub-score
adjusted for day 1 value (?SE) during the study (FAS).
p values indicate signiﬁcant scores. FAS full analysis set,
HAM-A Hamilton Anxiety Rating Scale, SE standard
error
b
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AEs, and especially after medication
discontinuation, and (4) no significant
predictors of treatment response were found.
The efficacy of alprazolam in ADWA is
consistent with prior findings that
benzodiazepines are efficacious in the
treatment of this condition. The early onset of
action of alprazolam is also consistent with
knowledge of the pharmacology of this agent
[9]. The finding that alprazolam may be
particularly effective for somatic symptoms of
anxiety (Fig. 3) is similarly consistent with
earlier work [30]. Although the cutoff of 2.5
for demonstrating the non-inferiority was based
on prior work, it is relevant to emphasize that
this is not universally agreed upon figure; a
more conservative cutoff of 4 has been used in
work comparing venlafaxine to placebo for
anxiety disorders [31]. Furthermore, ongoing
caution is warranted given the lack of placebo-
controlled data showing the efficacy of
benzodiazepines in ADWA [32], and concerns
about the potential for dependence [9].
The efficacy of etifoxine in ADWA is also
consistent with prior findings, which have
indicated non-inferiority for this agent
compared with buspirone [16] and lorazepam
[17], using a design very similar to the current
one. In those prior studies, when compared to
buspirone or lorazepam, more patients were
responders or clinical improvement was better
on the primary outcome analysis with etifoxine,
there was no difference in speed of onset, and
anxiety rebound was greater with lorazepam
than etifoxine. Secondary outcome measures in
the current study support the early efficacy of
etifoxine, and the predictor analysis failed to
find a relationship between treatment type
(alprazolam or etifoxine) and response to
treatment at day 28. More importantly, while
HAM-A and CGI scores decreased after
treatment discontinuation in the etifoxine
group, they increased in the alprazolam group,
with a significant difference between groups in
change between day 28 and day 35.
The safety profile of etifoxine and
alprazolam is again consistent with prior work
on these agents [17]. Thus, it is notable that
treatment-emergent adverse events were more
likely to occur in the alprazolam group, and
these were significantly more likely to be
considered treatment-related by clinicians.
Furthermore, more CNS-related adverse events,
such as somnolence or sedation, were reported
in the alprazolam group, although this
difference did not reach statistical significance.
Finally, the higher proportion of patients with
adverse events in the alprazolam group was
particularly apparent after treatment
discontinuation. These findings are consistent
with consensus statements that highlight
cognitive adverse events and the potential for
dependence with benzodiazepines [9]. In
contrast, etifoxine has a relatively safe adverse
event profile, and has the significant clinical
advantage of having anxiolytic properties,
while not being associated with potential for
dependence.
In general, it may be pointed out that much
remains to be learned about the treatment of
ADWA. The predictor analysis provided here
showed no significant predictors of clinical
response, indicating that drug treatment may
be useful in both less and more severe anxiety.
With a larger sample size, depression scores may
have significantly predicted worse response,
and certainly antidepressants may be
considered in anxious patients with an
elevated MADRS score. There is also a
significant need for cost-efficiency data and for
long-term follow-up. In the interim, however,
the current data support the efficacy and safety
of etifoxine in the treatment of ADWA. While
benzodiazepines such as alprazolam may also be
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reasonable to consider, etifoxine was associated
with fewer CNS-related adverse effects, and no
rebound effect after treatment discontinuation,
and therefore is an important alternative
approach for the management of ADWA.
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